Vertex Obtains EMA Validation to Expand Indications for Kaftrio

Vertex expands the indication of its drug to combat cystic fibrosis. The Committee for Human Use (Chmp) of the European Medicines Agency (EMA) has issued a positive opinion for the extension of the indication for Kaftrio in combination with ivacaftor, expanding the range of treatment for cystic fibrosis in children from two to five years.

In the European Union, Kaftrio in combination with ivacaftor is already approved for the treatment of people with cystic fibrosis for children aged six years and older. If this positive opinion is ratified and use in children under five years of age is authorized, Vertex assures that more than 1,200 children would be candidates to receive a medication that could treat the underlying cause of their illness.

Sara Alonso, medical director of Vertex, noted that “treating the underlying cause of cystic fibrosis as soon as possible has the potential to slow the progression of the disease, which is why we welcome the fact that the Chmp supports the extension of the indication for Kaftrio to patients as young as two years,” in the words of the company director.

Read more about Vertex and find the latest business news of the day with the Born2Invest mobile app.

In the European Union, Vertex’s drug is already approved for children six years and older

Cystic fibrosis is a genetic disease that affects more than 88,000 people worldwide. Specifically, in a progressive condition that damages multiple organs, including the lungs, liver, pancreas, or gastrointestinal tract. The disease is caused by a defective or missing Cftr (cystic fibrosis transmembrane conductance regulator) protein and life expectancy is approximately thirty years.

Vertex is a global biotechnology company that invests in scientific innovation to create medicines for people with serious diseases. The company has multiple medications approved to treat cystic fibrosis and several clinical and research programs underway to try to better understand the disease.

The company was founded in 1989 in Cambridge (Massachusetts). The global headquarters is located in Boston’s Innovation District and its international headquarters is located in London. In the financial results for the second quarter of the year, the firm reported product revenues of $2.49 billion, an increase of 14% compared to the same period of the previous year. In its forecasts, Vertex predicts closing the year with revenues of $9.8 billion.

_

(Featured image by jarmoluk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.